A5087182865- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Melanoma and MAPK Pathways
- CAR-T cell therapy research
- Immune cells in cancer
- Nanoplatforms for cancer theranostics
- Glioma Diagnosis and Treatment
- Virus-based gene therapy research
- Poxvirus research and outbreaks
- Histone Deacetylase Inhibitors Research
- Inflammation biomarkers and pathways
Front Range Community College
2021
Wilford Hall Ambulatory Surgical Center
2004-2006
9536 Background: Myeloid-derived suppressor cells (MDSCs) are potent suppressors of antitumor immunity and commonly associated with poor outcomes in melanoma patients treated immune checkpoint inhibitors. Inducing the differentiation MDSCs using all-trans retinoic acid (ATRA) reduces MDSC frequency. This analysis seeks to assess safety efficacy combining ATRA pembrolizumab advanced patients. Methods: single arm, institution, phase I/II study (NCT03200847) enrolled 24 diagnosed stage IV...
Objective: The goal was to discuss the potential risk of progressive vaccinia in setting smallpox vaccination with immunosuppression and present strategies avoid vaccinia. Methods: A case report literature review are presented. Results: 21-year-old, male, military member received coincidentally diagnosed as having osteosarcoma ∼2 weeks later. His recent recognized, chemotherapy subsequently delayed until separation scab at site. patient neoadjuvant fared well, without any evidence or other...
Abstract Myeloid-derived suppressor cells (MDSCs) are potent suppressors of antitumor immunity and commonly associated with poor outcomes in melanoma patients treated immune checkpoint inhibitors. Inducing the differentiation MDSCs using all-trans retinoic acid (ATRA) alters their activity reduces MDSC frequency. This trial seeks to assess safety efficacy combining ATRA pembrolizumab metastatic patients. In 24 stage IV patients, treatment Q3W plus supplemental orally for three days...
<p>Supplementary figure 1. (A) Changes in other circulating cytokines. Colored box denotes the time when patients were being treated with ATRA. (B) example gating strategy for CD8+ T cell activation.</p>
<p>Supplementary figure 2. Changes in other clinical hematologic measures. Colored box denotes the time when patients were being treated with ATRA. * Denotes p < 0.05, ** 0.01, *** 0.001, **** 0.0001.</p>
<div>AbstractPurpose:<p>A phase Ib/II clinical trial was conducted to evaluate the safety and efficacy of combination all-trans retinoic acid (ATRA) with pembrolizumab in patients stage IV melanoma.</p>Patients Methods:<p>Anti–PD-1 naïve melanoma were treated plus supplemental ATRA for three days surrounding each first four infusions. The primary objective establish MTD recommended II dose (RP2D) combination. secondary objectives describe toxicity combined treatment...
<p>Supplementary figure 1. (A) Changes in other circulating cytokines. Colored box denotes the time when patients were being treated with ATRA. (B) example gating strategy for CD8+ T cell activation.</p>
<p>Supplementary figure 2. Changes in other clinical hematologic measures. Colored box denotes the time when patients were being treated with ATRA. * Denotes p < 0.05, ** 0.01, *** 0.001, **** 0.0001.</p>
<div>AbstractPurpose:<p>A phase Ib/II clinical trial was conducted to evaluate the safety and efficacy of combination all-trans retinoic acid (ATRA) with pembrolizumab in patients stage IV melanoma.</p>Patients Methods:<p>Anti–PD-1 naïve melanoma were treated plus supplemental ATRA for three days surrounding each first four infusions. The primary objective establish MTD recommended II dose (RP2D) combination. secondary objectives describe toxicity combined treatment...
<div>AbstractPurpose:<p>A phase Ib/II clinical trial was conducted to evaluate the safety and efficacy of combination all-trans retinoic acid (ATRA) with pembrolizumab in patients stage IV melanoma.</p>Patients Methods:<p>Anti–PD-1 naïve melanoma were treated plus supplemental ATRA for three days surrounding each first four infusions. The primary objective establish MTD recommended II dose (RP2D) combination. secondary objectives describe toxicity combined treatment...
<p>Supplementary figure 2. Changes in other clinical hematologic measures. Colored box denotes the time when patients were being treated with ATRA. * Denotes p < 0.05, ** 0.01, *** 0.001, **** 0.0001.</p>
<p>Supplementary figure 1. (A) Changes in other circulating cytokines. Colored box denotes the time when patients were being treated with ATRA. (B) example gating strategy for CD8+ T cell activation.</p>